[68Ga] B7H3 Affibody-BCH(Beijing Cancer Hospital)

N/A

Report date: 2025/11/21 17:16:30

Base Information

Drug Name[68Ga] B7H3 Affibody-BCH(Beijing Cancer Hospital)

Drug Alias NameB7-H3 Targeted Affibody Radioligand Probes(Beijing Cancer Hospital)

ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68GaBiologics > Protein drugs +[4]

Mechanisms of ActionPositron-emission tomography enhancersCD276 antigen modulators

TargetsCD276 antigen

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesBeijing Cancer Hospital

China Registration ClassN/A

Develop Information

Active CompaniesBeijing Cancer Hospital

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A